Pharmacokinetics of SARS‐CoV‐2 RNA Polymerase Inhibitor Remdesivir in Participants With Moderate and Severe Hepatic Impairment

Ejemplares similares

• Characterization of Drug–Drug Interactions for Remdesivir, an Intravenous Antiviral for SARS‐CoV‐2, in Healthy Participants
  por: Jack Chang, et al.
  Publicado: (2025)
• Pharmacokinetics, Mass Balance, Safety, and Tolerability of Obeldesivir in Healthy Participants
  por: Olena Anoshchenko, et al.
  Publicado: (2024)
• Pharmacokinetics and Safety of Firsocostat, an Acetyl‐Coenzyme A Carboxylase Inhibitor, in Participants with Mild, Moderate, and Severe Hepatic Impairment
  por: Islam R. Younis, et al.
  Publicado: (2024)
• Developing Allosteric Inhibitors of SARS‐CoV‐2 RNA‐Dependent RNA Polymerase
  por: Artem Chayka, et al.
  Publicado: (2024)
• Allosteric Inhibitors of SARS‐CoV‐2 RNA‐Dependent RNA Polymerase Based on N , N′ ‐Diphenylurea
  por: Artem Chayka, et al.
  Publicado: (2025)